TY - JOUR

T1 - ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

AU - Montalban, Xavier

AU - Gold, Ralf

AU - Thompson, Alan J

AU - Otero-Romero, Susana

AU - Amato, Maria Pia

AU - Chandraratna, Dhia

AU - Clanet, Michel

AU - Comi, Giancarlo

AU - Derfuss, Tobias

AU - Fazekas, Franz

AU - Hartung, Hans Peter

AU - Havrdova, Eva

AU - Hemmer, Bernhard

AU - Kappos, Ludwig

AU - Liblau, Roland

AU - Lubetzki, Catherine

AU - Marcus, Elena

AU - Miller, David H

AU - Olsson, Tomas

AU - Pilling, Steve

AU - Selmaj, Krysztof

AU - Siva, Axel

AU - Sorensen, Per Soelberg

AU - Sormani, Maria Pia

AU - Thalheim, Christoph

AU - Wiendl, Heinz

AU - Zipp, Frauke

PY - 2018

Y1 - 2018

N2 - BACKGROUND: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.OBJECTIVES: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.METHODS: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.RESULTS: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.CONCLUSION: The present guideline will enable homogeneity of treatment decisions across Europe.

AB - BACKGROUND: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.OBJECTIVES: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.METHODS: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.RESULTS: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.CONCLUSION: The present guideline will enable homogeneity of treatment decisions across Europe.

U2 - 10.1177/1352458517751049

DO - 10.1177/1352458517751049

M3 - Journal article

C2 - 29353550

VL - 24

SP - 96

EP - 120

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 2

ER -